Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Vela Technologies Plc LSE:VELA London Ordinary Share GB00BYZ9XC29 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.005 6.06% 0.0875 0.085 0.09 0.0875 0.0825 0.0825 130,803,536 15:51:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 0.0 -0.2 -0.0 - 11

Vela Technologies PLC Update re. St George Street Capital COVID-19 trial

11/01/2021 7:00am

RNS Non-Regulatory


TIDMVELA

Vela Technologies PLC

11 January 2021

Reach- non-regulatory announcement

Vela Technologies plc

("Vela" or "the Company")

Update re. St George Street Capital Limited COVID-19 trial

The Board of Vela notes the recent update published by St George Street Capital Limited ("SGS") and is pleased with the progress made and the approval received in Czech Republic and Romania in relation to its ARCADIA clinical trial to test SGS002 ("the Asset"), a drug that could be beneficial to diabetic patients suffering from COVID-19.

The full announcement can be found in the News segment of the SGS website, https://www.sgscapital.org/ , and is copied below.

Details of Vela's economic interest in the potential commercialisation of the Asset, the Asset and the ARCADIA trial were included in the announcement published by Vela on 20 October 2020.

SGS holds 1,100,000,000 ordinary shares in Vela, representing 9.11 per cent. of Vela's issued share capital. These ordinary shares are subject to a lock-in agreement until the successful completion of Phase II of the ARCADIA trial, or for a period of two months following completion of the ARCADIA trial, should the outcome of the trials not meet the minimum threshold.

The update issued by SGS is reproduced in full below:

Covid-19 Trial Update - 04-01-21

Approval Received to Begin Recruiting in Czech Republic and Romania

The ARCADIA clinical trial is a randomised, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes and admitted to hospital with COVID-19. The trial, which is sponsored by the UK charity St George Street, has successfully recruited 50 of the planned 150 patients across 11 UK hospital sites over the past 3 months. To help ensure timely completion of study enrolment, the ARCADIA trial is now expanding with the addition of approximately 23 new hospital sites over the coming weeks. In addition to 4 new sites in the UK, up to 19 sites are to be opened in Czech Republic and Romania. Regulatory and ethics committee approval for both new countries was received at the end of December 2020 and the first patients from Czech Republic and Romania are expected to be recruited to ARCADIA before the end of January 2021.

Both Czech Republic and Romania have a high prevalence of diabetes (10.2% and 8.8% of the population having diabetes respectively), this compares with around 6.5% of people in the UK. In addition, both countries have regularly reported over 100 deaths from COVID-19 per day throughout December, indicating a high unmet clinical need.

The decision and rapid action to obtain approval in Romania and Czech Republic is testament to the strength of the St George Street team and its collaborative relationships with its development partners. St George Street is delighted to have received such rapid regulatory approval in the two new countries and looks forward to collaborating closely with the investigational teams in both countries.

The mechanism of actions of AZD1656, both blood glucose lowering and potential immunomodulatory action, are independent of viral mutations. AZD1656 activates glucokinase, which is expected to increase the migration of T regulatory cells in addition to reducing blood glucose. Reducing hyperglycaemia (high blood glucose) is increasingly seen to be important to improve outcomes in people with diabetes and COVID-19. Migration of regulatory T cells is expected to dampen down the hyperinflammation seen in the lungs for instance, that results in severe COVID-19.

Dave Tapolczay, CEO of St George Street said 'I am delighted with the progress of the ARCADIA trial so far in the UK and through adding an additional 23 hospital sites we expect to see a significant impact on patient recruitment of the trial. Credit must go to the team in obtaining regulatory approval so quickly in Czech Republic and Romania. As a society we will need many solutions to battle the surging pandemic and I am proud that here at St George Street we are playing our part in helping to find those solutions.'

For further information, please contact:

 
 Vela Technologies plc                         Tel: +44 (0) 7421 
  Brent Fitzpatrick, Non-Executive Chairman     728875 
  James Normand, Executive Director 
 Allenby Capital Limited (Nominated Adviser    Tel: +44 (0) 20 
  and Joint Broker)                             3328 5656 
 Nick Athanas/Asha Chotai 
 Peterhouse Capital Limited (Joint Broker)     Tel: +44 (0) 20 
  Lucy Williams / Duncan Vasey / Eran Zucker    7469 0930 
 

About Vela Technologies

Vela Technologies (AIM: VELA) is an investing company focused on early stage and pre-IPO long term disruptive technology investments. Vela's investee companies have either developed ways of utilising technology or are developing technology with a view to disrupting the businesses or sector in which they operate. More recently, Vela Technologies has also started to focus on existing listed companies where valuations may offer additional opportunities.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAZZGGMZRRGMZZ

(END) Dow Jones Newswires

January 11, 2021 02:00 ET (07:00 GMT)

1 Year Vela Technologies Chart

1 Year Vela Technologies Chart

1 Month Vela Technologies Chart

1 Month Vela Technologies Chart
ADVFN Advertorial
Your Recent History
LSE
VELA
Vela Techn..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210303 18:53:59